Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
Between many corporations, the Palisade Bio Inc disclosed as well the second quarter of 2022 numbers
company announced second quarter of 2022 operating shortfall of $-3.572 million
Published Aug 17 2022
CSIMarket Team / CSIMarket.com
It is eye-catching that, the emerging growth company did operate more economically, then in the comparable period a prior year. Coming from operating shortfall of $-32.858 million.
Now, there was also some alleviation on the deficit. as the deficit has been reduced from the time frame, a year prior. It is a essential observation in the financial second quarter of 2022. Shortfall was $-2.344 million, while in the second quarter of 2021 $-31.746 million.
Palisade Bio Inc is expected to report next financial recent numbers on May 12, 2023.
Other PALI's news
PALI Achieves Record-Breaking Third Quarter 2023 Earnings: Biotech & Pharma Industry in Evolution
Palisade Bio Inc Builds Momentum with Aggressive Spending Despite Operating Losses
Between many corporations, the Palisade Bio Inc disclosed as well the second quarter of 2022 numbers
The Biotechnology & Pharmaceuticals company announced operating loss in the first quarter of 2022
Other PALI's news
PALI Achieves Record-Breaking Third Quarter 2023 Earnings: Biotech & Pharma Industry in Evolution
Palisade Bio Inc Builds Momentum with Aggressive Spending Despite Operating Losses
Between many corporations, the Palisade Bio Inc disclosed as well the second quarter of 2022 numbers
The Biotechnology & Pharmaceuticals company announced operating loss in the first quarter of 2022